FROM Aaron Kesselheim
An old drug gets a ridiculously high price….again Are incentives for so-called "orphan drugs" being misused to jack up the price of one medication by 4000 percent? Photo by Chris Potter A rare form of muscular dystrophy has long been treated in the US by a steroid imported from overseas at a price of $1200 a year. Now the FDA has approved its manufacture and distribution in this country by the drug company Marathon. The new price is $89,000 a year — reduced to $54,000 after rebates and discounts. We get perspective from Carolyn Johnson, who covers the business of medicine for the Washington Post , and Dr. Aaron Kesselheim, a professor of medicine at Harvard, where he's also Director of the program on Regulation, Therapeutics and Law.
Doctors, Drug Companies and Transparency In an effort to get doctors to prescribe their drugs to patients, drug makers spend billions of dollars a year on meals, speaking and consulting fees, and other perks for physicians. Today, a new government database goes online that will list the money pharmaceutical companies spend on doctors.
Russian probe gets jolt from Yates and Clapper Senate hearing Intelligence officials have long since concluded that Russia interfered in last year's US election. After yesterday's Senate Judiciary Committee hearing, what more do we know about the threat to future elections and how it's being handled by the Trump Administration?
Healthcare debate now shifts to the Senate Both parties are celebrating yesterday's House bill to repeal and replace Obamacare. House Republicans are cheering because they were able to pass it. Democrats are happy because they think it's so bad. We look at the details… and the politics.